New daily pill HEC585 aims to slow lung scarring in IPF
NCT ID NCT07082842
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new drug called HEC585, taken once daily, to see if it can slow lung function decline in people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 472 adults aged 40 to 80 will be randomly assigned to receive HEC585, a placebo, or the existing drug pirfenidone. The main goal is to measure changes in lung capacity after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HEC585 tablet
- What this could lead to
- If it works, this could offer a new once-daily treatment option to slow lung function decline in people with idiopathic pulmonary fibrosis.
- What could go wrong
- This is an early Phase 3 trial, so results are not yet proven. The drug may not work better than existing treatments or could have side effects. IPF is a complex disease, and many experimental drugs have failed before.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Can a new drug slow lung scarring in IPF?
- Blood tests could unlock early clues for three major lung diseases
- AI could uncover hidden lung disease in routine chest X-Rays
- Inhaled drug could offer new hope for lung scarring disease
- New hope for lung scarring: AZD8965 enters Mid-Stage trial